pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 21·1 min read
save

Nabla appoints former Bamboo Health president Brian Manning as CEO to boost US market push

Jul 21, 2026·read at STAT ↗Neutral

Nabla, the Paris‑based maker of ambient AI scribes for clinical documentation, announced that Brian Manning will take over as chief executive officer.

Manning comes from a background in care‑coordination software, having served as chief revenue officer at PatientPing and later as president of Bamboo Health after its acquisition. The company says his hire marks the next phase of its go‑to‑market strategy.

Looking ahead to 2027, Nabla plans to build its brand in the United States and accelerate market entry, betting on its proprietary "world models" technology as an alternative to large language models.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment”

read at STAT ↗
533 words · retrieved Jul 21
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ELI LILLY COLILLYNOVONovo Nordisk IncUltragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
GLP-1 receptorRare Disease

related stories

  • Sep 23Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • Sep 22Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsBioSpace
  • Sep 14Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrandBioSpace
  • Sep 8Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropBioSpace
  • Aug 28Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist MounjaroBioSpace